United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $259.70, for a total transaction of $934,920.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $33,761. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
United Therapeutics Trading Up 2.2 %
United Therapeutics stock traded up $5.71 during trading hours on Tuesday, reaching $266.22. The stock had a trading volume of 591,917 shares, compared to its average volume of 462,599. The company has a fifty day simple moving average of $237.59 and a 200-day simple moving average of $229.59. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $266.65. The stock has a market cap of $11.81 billion, a PE ratio of 12.32 and a beta of 0.54. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. United Therapeutics’s quarterly revenue was up 33.7% on a year-over-year basis. During the same period last year, the firm earned $4.86 earnings per share. Analysts forecast that United Therapeutics Co. will post 23.88 EPS for the current fiscal year.
Analysts Set New Price Targets
View Our Latest Stock Report on United Therapeutics
Hedge Funds Weigh In On United Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in UTHR. Norges Bank bought a new position in United Therapeutics in the 4th quarter worth $100,519,000. Nordea Investment Management AB lifted its holdings in United Therapeutics by 677.6% in the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after buying an additional 262,222 shares during the period. Avidity Partners Management LP bought a new stake in United Therapeutics during the 4th quarter valued at approximately $52,158,000. LSV Asset Management grew its holdings in shares of United Therapeutics by 40.3% during the 1st quarter. LSV Asset Management now owns 529,519 shares of the biotechnology company’s stock worth $121,641,000 after acquiring an additional 152,151 shares during the period. Finally, Comerica Bank raised its position in shares of United Therapeutics by 2,697.2% in the 3rd quarter. Comerica Bank now owns 156,587 shares of the biotechnology company’s stock worth $35,368,000 after acquiring an additional 150,989 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Articles
- Five stocks we like better than United Therapeutics
- How to Invest in the Best Canadian StocksĀ
- Garmin Navigates to New Highs Driven By Wearables Trend
- Industrial Products Stocks Investing
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- EV Stocks and How to Profit from Them
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.